Alocef-CV Dry
Cefpodoxime is a third-generation cephalosporin antibiotic, and Clavulanate is a beta-lactamase inhibitor. This combination is used to treat bacterial infections by both combating the bacteria and inhibiting bacterial enzymes (beta-lactamases) that could degrade cefpodoxime, enhancing its efficacy.
This formulation is typically used in pediatric patients or others who may have difficulty swallowing tablets, as it comes in a suspension form.
- Recommended Usage
Indications
- Upper Respiratory Tract Infections: Including sinusitis, pharyngitis, and tonsillitis.
- Lower Respiratory Tract Infections: Such as bronchitis and pneumonia.
- Urinary Tract Infections: Cystitis and pyelonephritis caused by beta-lactamase-producing pathogens.
- Skin and Soft Tissue Infections: Infections such as cellulitis and wound infections caused by susceptible organisms.
- Ear Infections: Otitis media, particularly in children, caused by beta-lactamase-producing organisms.
- Other Infections: Infections caused by bacteria that produce beta-lactamase and are resistant to non-beta-lactamase-inhibitor cephalosporins.
Dosage and Administration
The usual dose is typically 1 teaspoon (approximately 5 mL) of the suspension containing 50 mg of Cefpodoxime and 31.25 mg of Clavulanate, every 12 hours. This dosage may vary according to the physician’s recommendation, based on the infection type and severity.
Dosage in children is usually determined by body weight. A typical dose for children may be calculated based on 8 mg/kg of Cefpodoxime divided into two doses taken every 12 hours.
Ensure the suspension is shaken well before each dose to ensure the correct dosage is administered.
Precautions
This combination should be avoided in patients with a known allergy to cephalosporins or penicillins due to potential cross-reactivity.
Cefpodoxime is primarily excreted via the kidneys, so caution is required in patients with impaired renal function. Dosage adjustments may be necessary, and renal function should be monitored throughout treatment.
Caution is advised in patients with liver dysfunction, as Clavulanate can affect liver enzymes. Hepatic function should be monitored if therapy is prolonged.
Both Cefpodoxime and Clavulanate may cause gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain.
Benefits
Broad-Spectrum Antibiotic: Combines Cefpodoxime (a third-generation cephalosporin) with Clavulanate, making it effective against a variety of bacterial infections, including respiratory, urinary tract, skin, and ear infections.
Enhanced Efficacy: Clavulanate prevents Cefpodoxime from being degraded by beta-lactamase enzymes, improving effectiveness against beta-lactamase-producing resistant bacteria.
Convenient Liquid Form: The dry suspension is ideal for pediatric use or for individuals who cannot swallow tablets, making it easy to administer.
Effective Against Resistant Bacteria: Provides treatment for infections caused by resistant bacteria that would otherwise be difficult to treat with standard antibiotics.
Well-Tolerated: Generally well-tolerated with mild side effects like gastrointestinal upset (e.g., nausea, diarrhea).
